Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) fell 3.5% during trading on Wednesday . The stock traded as low as $10.39 and last traded at $10.22. 444 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 6,095 shares. The stock had previously closed at $10.59.
Wall Street Analysts Forecast Growth
Several brokerages have commented on PHAR. Oppenheimer boosted their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th.
Read Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
The firm's 50-day moving average price is $10.53 and its 200-day moving average price is $9.45. The company has a current ratio of 2.76, a quick ratio of 2.00 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $683.71 million, a PE ratio of -50.25 and a beta of 0.02.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The company had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. On average, equities analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,147 shares of the company's stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.